Fig. 3From: CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trialTreatment response and survival outcomes. Kaplan-Meier curves showed (a) progression-free survival and (b) overall survival of the CEOP/IVE/GDP group and of the CEOP group. HR = hazard ratioBack to article page